Sachin Kumar, MD
Interventional Cardiology · Houston, TXNPI 1528231628
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 70.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $6,420 and has fallen 84.8% since, to $975 in 2025.
Across 122 payments — averaging $105.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Abiomed$1K
- Boston Scientific$950
- Medtronic$488
- Teleflex LLC$240
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$177
- plus $680 from 13 others
Across 41 payments — averaging $10,568 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$226K
- Abbott$207K
- Abiomed$234
What the payments were for
- Consulting fees$4,08032%
- Travel & lodging$1,65713%
- Food & beverage$7,19256%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 66 | $9,048 |
| Abiomed | 8 | $1,346 |
| Boston Scientific | 14 | $950 |
| Medtronic(2 entities) | 9 | $488 |
| Teleflex LLC | 2 | $240 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $177 |
| Impulse Dynamics (USA) Inc. | 2 | $126 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Amgen | 1 | $118 |
| Merck | 4 | $74 |
| Edwards Lifesciences | 2 | $55 |
| AstraZeneca | 2 | $36 |
| Imperative Care, Inc | 1 | $28 |
| Analog Devices Inc. | 1 | $25 |
| United Therapeutics Corporation | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$4,536
- Impella$1,215
- CentriMag$680
- Advisor Catheter$476
- GENERAL VASCULAR ACCESS$470
- Agilis NxT EP Introducer$303
- Angio-Seal Vascular Closure Dev$278
- ADVISOR$257
- MANTA$240
- Agilis HisPro$153
- Quadra Assura CRT Defibrillator$149
- HeartMate 3 Left Ventricular Dev$141
- Resolute$133
- XIENCE SKYPOINT$129
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$126
- UPTRAVI$125
- KRYSTEXXA$118
- Confirm Rx$115
- Trifecta GT Tissue Heart Valve$113
- Xience Sierra Coronary Stent$104
How this compares
$12,929 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 66 | $84,242 |
| EliquisApixaban | 65 | $75,531 |
| JardianceEmpagliflozin | 55 | $61,860 |
| FarxigaDapagliflozin Propanediol | 57 | $57,153 |
| BrilintaTicagrelor | 38 | $25,757 |
| Ranolazine ErRanolazine | 12 | $3,004 |
| Potassium Chloride | 60 | $2,057 |
| Bumetanide | 30 | $1,896 |
| Metoprolol Succinate | 118 | $1,839 |
| Torsemide | 39 | $1,316 |
| Atorvastatin Calcium | 116 | $1,206 |
| Ezetimibe | 25 | $1,008 |
| ClopidogrelClopidogrel Bisulfate | 55 | $675 |
| Spironolactone | 52 | $634 |
| Rosuvastatin Calcium | 25 | $542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $36 | $82,91095 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.